checkAd

     169  0 Kommentare Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI - Seite 3

    Investor Contact
    Alex Khan
    VP, Finance & Investor Relations
    investors@absci.com

    Lesen Sie auch

    Media Contact
    press@absci.com



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI - Seite 3 IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly afterVANCOUVER, Wash. and NEW YORK, Feb. 21, 2024 (GLOBE NEWSWIRE) - Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today …